These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20970833)

  • 21. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
    Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
    BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Trospium chloride once daily for overactive bladder syndrome: results of a multicenter observational study].
    Notz HJ; Hautumm B; Werdier D; Groves R; Odenthal KP
    Urologe A; 2013 Jan; 52(1):65-70. PubMed ID: 23052979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
    Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
    BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Experience with application of trospium chloride in patients with neurogenic detrusor overactivity].
    Shvarts PG; Kadykov AS; Shvedkov VV; Timerbaeva SL; Polevaia EV; Mulach AN
    Urologiia; 2009; (5):24-9. PubMed ID: 20213911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The overactive bladder-symptom composite score: a composite symptom score of toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder.
    Zinner N; Harnett M; Sabounjian L; Sandage B; Dmochowski R; Staskin D
    J Urol; 2005 May; 173(5):1639-43. PubMed ID: 15821526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A; Wyndaele JJ; Sieber P
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
    Staskin DR; Dmochowski RR; Sand PK; Macdiarmid SA; Caramelli KE; Thomas H; Hoel G
    J Urol; 2009 Apr; 181(4):1764-72. PubMed ID: 19233423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Trospium Chloride on Cognitive Function in Women Aged 50 and Older: A Randomized Trial.
    Geller EJ; Dumond JB; Bowling JM; Khandelwal CM; Wu JM; Busby-Whitehead J; Kaufer DI
    Female Pelvic Med Reconstr Surg; 2017; 23(2):118-123. PubMed ID: 28067745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trospium chloride for the treatment of overactive bladder with urge incontinence.
    Singh-Franco D; Machado C; Tuteja S; Zapantis A
    Clin Ther; 2005 May; 27(5):511-30. PubMed ID: 15978301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice-daily trospium chloride 20 mg in healthy adults.
    Silver N; Sandage B; Sabounjian L; Schwiderski U; Shipley J; Harnett M
    J Clin Pharmacol; 2010 Feb; 50(2):143-50. PubMed ID: 19948948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder.
    Staskin D; Kay G; Tannenbaum C; Goldman HB; Bhashi K; Ling J; Oefelein MG
    Int J Clin Pract; 2010 Aug; 64(9):1294-300. PubMed ID: 20561092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'.
    Lee KS; Lee HW; Choo MS; Paick JS; Lee JG; Seo JT; Lee JZ; Lee YS; Yoon H; Park CH; Na YG; Jeong YB; Lee JB; Park WH
    BJU Int; 2010 Jun; 105(11):1565-70. PubMed ID: 19912183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
    Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
    BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial.
    Wagg A; Khullar V; Marschall-Kehrel D; Michel MC; Oelke M; Darekar A; Bitoun CE; Weinstein D; Osterloh I
    J Am Geriatr Soc; 2013 Feb; 61(2):185-93. PubMed ID: 23350833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
    Rovner ES; Kreder K; Sussman DO; Kaplan SA; Carlsson M; Bavendam T; Guan Z
    J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial.
    Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM;
    Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist.
    Steers W; Corcos J; Foote J; Kralidis G
    BJU Int; 2005 Mar; 95(4):580-6. PubMed ID: 15705084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.